GE HealthCare Expands Contrast Media Portfolio with Launch of MRI Agent Pixxoscan (gadobutrol)
27.4.2023 09:00:00 EEST | Business Wire | Press release
GE HealthCare has today announced the launch of Pixxoscan (gadobutrol), its macrocyclic, non-ionic Magnetic Resonance Imaging (MRI) gadolinium-based contrast agent (GBCA). Pixxoscan has been reviewed using a regulatory decentralized procedure (DCP) with marketing authorization already in place in Austria and pending approval, will be introduced to a number of European countries in 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005641/en/
Enhanced Magnetic Resonance (MR) procedure with cardiac scan images (Photo: Business Wire)
It has been reviewed as having the same qualitative and quantitative composition in active substance and excipients, and the same pharmaceutical form, as the reference product, Gadovist.
Pixxoscan facilitates visualization of abnormal structures or lesions and helps in the differentiation between healthy and pathological tissue. In line with the reference product, Gadovist, Pixxoscan (gadobutrol) is indicated for use in adults, adolescents, and children of all ages (including term neonates) for contrast enhancement in cranial and spinal MRI and magnetic resonance angiography. It is also indicated for whole body imaging, including liver and kidneys in patients with high suspicion or evidence of having focal lesions to classify them as benign or malignant.
Gadobutrol has a high relaxivity which helps enhance detection, delineation and characterization in MRI across its range of indications. It is also formulated at twice the concentration of gadolinium ions, reducing injection volume by half compared to other GBCAs, providing a tighter bolus. Its cage-like macrocyclic chelate, which encloses the gadolinium, provides high kinetic stability.
Pixxoscan adds to GE HealthCare’s MRI contrast media portfolio which includes macrocyclic Clariscan (gadoteric acid) as well as Rapiscan, used in stress cardiac MR to aid diagnosis of coronary artery disease and offering an alternative for patients who cannot exercise. The availability of Pixxoscan will give radiology departments greater access to agents supporting a broad range of MRI procedures, helping them in personalizing care for patients.
Dr Gianluca Pontone, Director of Perioperative Cardiology and Cardiovascular Imaging Department, Monzino Cardiology Center, Milan, Italy, said: “GE HealthCare continues to expand its range of products and Pixxoscan sitting alongside cardiac stress agent, Rapiscan, is welcome news. This gives me, as a cardiologist, the products I need to aid in making timely diagnoses for patients with suspected coronary artery disease.”
Mark Hibberd, Chief Medical Officer, GE HealthCare Pharmaceutical Diagnostics, said: “This extension to our portfolio means, we will be able to offer two leading macrocyclic molecules – Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) - to our customers in a number of European countries, offering radiology departments even more choice to suit their diagnostic needs. We continue to innovate and invest in our contrast media portfolio to deliver for healthcare professionals and patients and to meet future demand.”
Pixxoscan (gadobutrol) offers a wide range of packaging encompassing glass vials, ready-assembled plastic prefilled syringes and larger volume +PLUSPAK polypropylene bottles. GE HealthCare’s +PLUSPAK plastic packaging, using flip-top lids, helps eliminate risk of, and downtime from, broken glass and ring-pull injuries. +PLUSPAK also provides more choice for customers and helps them reduce their costs and environmental impact.
As with all GE HealthCare contrast agents, Pixxoscan will be produced in compliance with current Good Manufacturing Practices (cGMP) - with rigorous testing at our primary and secondary manufacturing sites in Norway to ensure high quality. Once approved, it will then be labelled and packed for onward shipping via our standard distribution network to local markets.
GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE HealthCare imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005641/en/
Contact information
GE HealthCare Media Contact:
Debbie Leven
M +44 778 545 6999
Debbie.Leven@ge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Healthcare Accelerates AI Investment as Governance and Risk Shape the Path to Value19.11.2026 11:26:00 EET | Press release
HTEC, the global AI technology and engineering leader, today released new research examining how healthcare and life sciences organizations measure, track, and realize value from AI investments, as well as the risks and barriers preventing them from doing so at scale. The findings reveal that while investment continues to rise, organizations that successfully scale AI focus not only on technology, but also on the governance, workforce adoption, and operational foundations needed to track, prove, and realize impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119322683/en/ HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory complexity, validation requirements, and organizational readiness. The HTEC AI Value Realization Report 2026: Healthcare & Life Sciences found that among healthcare respondents currently pursuing AI adoption, 8
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 11:00:00 EET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 11:00:00 EET | Press release
Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to them right as the action happens on the pitch. With Twilio Segment, Chelsea is able to: Create Real-Time Offers: After Estêvão Willian’s extraordinary
EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 10:49:00 EET | Press release
Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI
Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 10:43:00 EET | Press release
Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloading a new app. The launch is part of Alipay+'s broader efforts to advance cross-border digital payment connectivity. Through its payment partners, Alipay+ links 150 million merchants with 2.1 billion user accounts globally. It also partners with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
